Preclinical safety evaluation of the dipeptidyl peptidase 3 inhibiting antibody Procizumab in rodents and non-human primates.

MAbs · 2026 · PMC13196631 · PMID 42166148

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a weak trendno p-value reported

For the highest dose, a weak trend toward a higher than dose-proportional increase (i.e., higher than the expected exposure ratio of 8.75) was observed between the low- and high-dose groups.

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.